Proceedings: Cell Therapies for Parkinson’s Disease From Discovery to Clinic

ROSA CANET-AVILES, GEOFFREY P. LOMAX, ELLEN G. FEIGAL, CATHERINE PRIEST

California Institute for Regenerative Medicine, San Francisco, California, USA

Key Words. Parkinson’s disease • Cell therapies • Clinical trials • Experimental models

ABSTRACT

In March 2013, the California Institute for Regenerative Medicine, in collaboration with the NIH Center for Regenerative Medicine, held a 2-day workshop on cell therapies for Parkinson’s disease (PD), with the goals of reviewing the state of stem cell research for the treatment of PD and discussing and refining the approach and the appropriate patient populations in which to plan and conduct new clinical trials using stem cell-based therapies for PD. Workshop participants identified priorities for research, development, and funding; discussed existing resources and initiatives; and outlined a path to the clinic for a stem cell-based therapy for PD. A consensus emerged among participants that the development of cell replacement therapies for PD using stem cell-derived products could potentially offer substantial benefits to patients. As with all stem cell-based therapeutic approaches, however, there are many issues yet to be resolved regarding the safety, efficacy, and methodology of transplanting cell therapies into patients. Workshop participants agreed that designing an effective stem cell-based therapy for PD will require further research and development in several key areas. This paper summarizes the meeting.

INTRODUCTION

In March 2013, the California Institute for Regenerative Medicine (CIRM), in collaboration with the Center for Regenerative Medicine of the NIH, held a 2-day workshop on cell therapies for Parkinson’s disease (PD), with the goals of reviewing the state of stem cell research for the treatment of PD and discussing and refining the approach and the appropriate patient populations in which to plan and conduct new clinical trials using stem cell-based therapies for PD.

The group comprised approximately 50 scientists, clinicians, cell manufacturers, clinical trial and regulatory experts as well as members of biotechnology and pharmaceutical industries and funding agencies and patient advocates (a list of attendees is shown in supplemental online Table 1). Pioneers and global leaders in the field presented their work and discussed the challenges and opportunities they have encountered in bringing experimental cell therapies for PD to the clinic.

Workshop participants identified priorities for research, development, and funding; discussed existing resources and initiatives; and outlined a path to the clinic for a stem cell-based therapy for PD. A consensus emerged among participants that the development of cell-replacement therapies for PD using stem cell-derived products could potentially offer substantial benefits to patients. As with all stem cell-based therapeutic approaches, however, many issues have yet to be resolved regarding the safety, efficacy, and methodology of transplanting cells as therapies for patients. Workshop participants agreed that designing an effective stem cell-based therapy for PD will require further research and development in the following areas:

- Identifying the best cell types to use as sources for the cellular therapeutic in future clinical trials (e.g., human induced pluripotent stem [hiPS] cells, human embryonic stem cells [hESCs], adult stem cells) and the degree of cell differentiation and purification required before transplantation;
- Optimizing conditions for engraftment, survival, and integration with existing neural circuitry in vivo;
- Understanding the ongoing glial and neuroinflammatory effects of progressive PD on the local environment and the effects on transplanted neurons and discussing the optimal immunotherapy needed to support the grafted cells;
- Standardizing the protocols and processes for optimal cell manufacturing;
- Developing standard surgical methods for cell transplantation that accurately and
effectively distribute the cells while causing minimal damage to the target region of the brain;
- Developing biological assays to assess the survival and efficacy of transplanted cells in vivo;
- Designing new functional clinical assessments to evaluate the success of potential interventions; and
- Identifying the most relevant considerations for the design of successful clinical trials (e.g., patient population, endpoints, monitoring, length of follow-up).

Breakout sessions provided a forum for participants to discuss all these points and to suggest additional opportunities for which synergy of efforts could improve the probability of success in bringing stem cell therapies to the clinic. Although participants agreed that collaboration is crucial for success in the field, they also indicated that supporting multiple approaches might increase the chance that a stem cell therapy for PD will translate to the clinic. The regulatory approval of a safe and effective product must first advance down the development pathway through a series of clinical trials. The workshop identified eight critical initial steps to facilitate development of a phase I/II clinical trial for stem cell therapy.

First, define the cell source. Either hiPS cells or hESCs could be used in the first stem cell trial. hESCs provide a more beneficial commercial model because a single hESC line can be banked in large quantities to treat multiple patients. hiPS cells can be autologous or allogeneic. Ideally, pluripotent stem cell banks should be matched to patients to minimize immune effects. Experiments to evaluate the different cell sources are under way, and several approaches are under investigation. Currently the effort is focused on prioritizing the different approaches and moving forward into clinical trials with the highest priority.

Second, choose a differentiation protocol that can produce functional authentic nigral A9 dopaminergic (DA) neurons. It will be critical to select a differentiation protocol that produces the right type of DA neuron both in vitro and in vivo in animal models. The method of differentiation is currently being optimized in different laboratories. Specifically, during characterization of cells through differentiation stages, there is a need to show robust expression of midbrain DA (mDA) neuron lineage markers (TH, Nurr1, Foxa2, Lmx1a, Pitx3, Engrailed1, Engrailed2) as well as mature neuronal markers in the final product, including Tuj1, synapsin, dopamine transporter (DAT), and G-protein coupled, inwardly rectifying potassium channel (GirK2). An important observation is that TH expression is shared among all catecholaminergic lineages and is not specific to midbrain. Other neuronal and non-neuronal fates should also be ruled out through marker expression.

Third, develop biological assays that predict in vivo functional activity and biological action. The likelihood of an effective approach for clinical application will increase when the functional features of authentic nigral A9 DA neurons are shown in the cell candidate. One such feature is an appropriate neurophysiological profile. Autonomous pacemaking or hyperpolarizing activated currents are primarily observed in A9 mDA neurons and represent a very important functional assay to be included in the in vitro characterization of the candidates in development. Another such feature is DA production and release in response to physiological stimuli. Measuring production and release of DA as well as its metabolites (DOPAC and HVA) with specific and sensitive techniques such as HPLC is necessary as part of the functional characterization assays of the candidate cell for transplantation. Finally, animal models should be used to optimize conditions for cell survival and to show integration (significant fiber outgrowth with synapse formation) and functional benefits. Long-term engraftment (minimum of 6 months) in an appropriate rodent model of PD (e.g., 6-hydroxydopamine [6-OHDA]-lesioned rat) and complete restoration of amphetamine-induced rotation behavior as well as significant improvements in at least two other motor performance behaviors need to be shown with the candidate cells. Further research is needed to define additional biomarkers and to develop potency assays that provide correlations between cell survival and predictive functional outcome.

Fourth, develop purification strategies. Purification of DA cells from other cells is also necessary to further enrich for DA neurons and obtain fully uniform populations at an optimized stage for transplantation. This will allow for better control of the ratio of serotoninergic (SER) to DA neurons in graft preparations and will avoid dyskinesias and preclude tumor formation.

Fifth, determine the minimum effective dose and the maximum feasible dose in large animal models. Preclinical experiments in large animal models should be conducted on the selected cell to optimize integration with existing neural circuitry and restoration of function. Although the number of cells required to replace the nigral cell loss is unclear, other cell therapy projects and fetal transplant experiments indicate that it is likely to be around 100,000 DA neurons, assuming they have the same innervation potential as fetal nigral DA cells.

Sixth, develop a consistent transplantation protocol that shows low risk of hemorrhage and no tumor formation. The first trial should involve bilateral transplantation into the putamen. The physician conducting the transplant would select the optimal method of transplantation, which may include the use of new transplantation devices, but the device for cell delivery is not thought to be a rate-limiting step for the phase I/II trial.

Seventh, select target patients for the phase I/II trial. Given the results from the fetal transplants trials, it seems clear that the target patients should ideally be younger patients who are early in their disease course and responsive to oral DA replacement therapies.

Eighth, select outcomes and follow-up studies for the phase I/II trial. Most participants agreed that the patients must be followed for at least 3 years after transplantation. Outcome parameters should include a variety of clinical measures along with magnetic resonance imaging (MRI) and positron emission tomography (PET).

Participants proposed that CIRM and NIH prioritize their funding efforts in the area of PD to support projects that will advance these research goals, especially around the generation of sufficiently large numbers of authentic DA nigral neurons such that stem cell-based therapies can be developed more rapidly as treatment options for PD.

Many researchers provided input during this workshop. Readers seeking more information about particular details and contacting researchers in certain areas may access that information by contacting the author.
Overview of the Incidence, Anatomy, and Symptomatology of PD

PD is the second most common neurodegenerative disorder in the world, affecting 1%–2% of the population aged older than 65 years and reaching a prevalence of almost 4% in those aged 85 years or older. It is characterized by progressive motor dysfunction expressed as a classic “resting tremor,” slowness of movements (bradykinesia), muscle rigidity, and difficulties with gait and balance [1]. PD patients also exhibit a variety of nonmotor features, including mood disturbances (e.g., depression, anxiety), dementia, pain, and sleep disturbances. Autonomic problems, including bladder or bowel dysfunction, sexual dysfunction, sweating abnormalities, and gastrointestinal abnormalities are also common. These nonmotor aspects arise at any stage of the disease and often present before motor features develop [2].

The primary signs of PD arise from damage to neuronal circuits in the basal ganglia involved in the precise control of motor function [3–5] (Fig. 1). The basal ganglia are a collection of nuclei composed of the striatum, globus pallidus, subthalamic nucleus, and substantia nigra. DA neurons of the substantia nigra pars compacta (SNc), the neurons progressively lost in PD, project to striatal medium spiny neurons and influence the activity of motor circuits running through the basal ganglia to the thalamus and cortex. Degeneration of DA neurons leads to a disruption of the delicate balance of excitatory and inhibitory feedback that is necessary for appropriate motor function (Fig. 1).

Clinically, the severity in PD is measured using the modified Unified Parkinson’s Disease Rating Scale (UPDRS), which is used to follow the longitudinal course of PD. This scale is the most commonly used in the clinical study of PD and tracks both motor and nonmotor features of the disease [6, 7]. The modified UPDRS consists of four broad scales that evaluate nonmotor experiences with daily living, motor experiences with daily living, motor features, and motor complications. Further research on the current clinical outcome measures is needed because difficulty interpreting the results of studies in recent years has been attributed to problems with the chosen outcome, given the natural variability in the scores that arise from UPDRS assessments [8].

The PD disease process in the brain can be staged postmortem using the Braak classification [9] by analyzing fixed tissue sections for the accumulation and regional distribution of α-synuclein and Lewy bodies (LBs), the pathological hallmark of PD. LBs are large, insoluble protein aggregates that result from the accumulation and aggregation of misfolded proteins, particularly α-synuclein [10]. The Braak system has been proposed as a method to stage the severity of PD based on observations of the regional distribution of LBs in the central nervous system [9, 11, 12].

A relationship between Braak staging and clinical severity has been difficult to establish, particularly given the fact that LBs are not universally observed in all forms of PD [13] and might not be in the right distribution for this classification.

Pathogenesis of PD: Cellular Mechanisms, Genetics, and Immune Effects

For many decades, PD was thought to be an idiopathic, late-adult-onset disease resulting from unknown environmental factors [14]. However, the identification in 1997 of Mendelian mutations in the SNCA gene [15], which codes for the α-synuclein protein that is deposited in the classic pathological lesion of PD, the LB.

Figure 1. Coronal section of the human brain showing the relevant regions (left) and circuits (right) underlying the direct and indirect motor pathways under normal physiologic conditions. Neurons in the primary motor cortex synapse project to medium spiny neurons in the striatum, which, in turn, regulate motor activity via two mutually antagonistic circuits known as the direct and indirect pathways (reviewed in [3, 4]). Abbreviations: GPe, external globus pallidus; GPi, internal globus pallidus; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; STR, striatum.
disorders, the composition of which varies according to specific protein aggregates that form in a number of neurodegenerative systems [22]. Although these genetic forms of PD are rare, composing approximately 3%–5% of cases [16], and can lack LB pathology, new and powerful genomewide association studies have mapped many new gene variants that alter the risk for PD, and geneticists predict that more may be discovered [16–19]. Consequently, genetic risk factors contribute to the etiology of even typical forms of PD [16].

What are the mechanisms responsible for the highly selective death of the SNc DA neurons in PD patients? Postmortem evaluation and, more recently, genetic and molecular studies have helped uncover the evidence for many possible mechanisms to explain the cellular pathogenesis of sporadic PD, which is likely to be complex, involving altered metabolism and possible spread of α-synuclein, lysosomal dysfunction, mitochondrial dysfunction, and possibly a dysregulated inflammatory response [20]. In terms of mitochondrial defects, these were found to be associated with the occurrence of classic PD symptoms that developed in young adults after self-exposure to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Later, mechanistic studies revealed that MPP+ (the actively toxic metabolite of MPTP) inhibits mitochondrial metabolism [21]. Substantial progress toward understanding the role of mitochondria in the disease process has been made by the identification and characterization of genes causing familial variants of PD. Studies of the function and dysfunction of these genes have revealed that various aspects of mitochondrial biology appear to be affected in PD, including mitochondrial biogenesis, bioenergetics, dynamics, transport, and the fidelity of the mitochondrial quality control systems [22].

Some genetic forms of PD directly impair mitochondrial function and thereby cause bioenergetic failure. Studies published over the last 7 years have established a model for the PINK1/Parkin pathway of mitochondria quality control [23]. Furthermore, data from IPS cell-derived neural cells from PD patients with LRRK2/PINK1 mutations have shown altered bioenergetic profiles and mitochondrial dynamics [24]; however, the precise mechanisms linking mitochondrial dysfunction to neuronal death in PD remain unclear. As described above, affected neurons in PD tend to accumulate large amounts of α-synuclein in the form of LBs [10]. LBs are one of several known types of insoluble protein aggregates that form in a number of neurodegenerative disorders; the composition of which varies according to specific disease (i.e., β-amyloid and tau in Alzheimer’s disease, TDP-43 in amyotrophic lateral sclerosis [ALS], and mutant huntingtin in Huntington’s disease [HD]; reviewed in [25]). Whether LBs actually cause disease or are a secondary coping response to disease pathogenesis is a matter of intense debate [13]. Early hypotheses, based on postmortem observations of PD brains, suggested that LBs within the neurons themselves might be linked to DA cell death [26]. Recent evidence, however, suggests that LBs might instead be essential for sequestering misfolded or dysfunctional proteins that otherwise cause cellular damage, and thus LBs might be protective [27]; similar observations have been made in HD models [28]. Other cellular mechanisms designed to manage the accumulation of such proteins, such as proteosomal degradation and autophagy, have been shown to be dysregulated in PD [24, 29, 30]. In this last area, the recognition that GBA mutations are quite common in sporadic PD has suggested that lysosomal dysfunction may be a much more important pathway for disease than previously thought.

DA neurons are also disproportionately vulnerable to oxidative damage and inflammatory effects. A distinguishing feature of nigrostriatal DA neurons is their increased reliance on intracellular oxidative processes related to the synthesis of dopamine [31], which makes them particularly susceptible to oxidative stress. This aspect was directly revealed in studies with hIPS cell-derived neurons from PD patients with PINK1/LRRK2 mutations, whereby patient-derived DA neurons were more vulnerable to pharmacologically induced oxidative stress than DA neurons from healthy controls [24, 32]. DA neurons also have increased iron content [33] and reduced levels of the antioxidant glutathione [34], which increases their susceptibility to oxidative stress [35], as well as specific calcium channels that may in some way link to disease [36]. In addition, there are more microglia, the resident macrophages of the central nervous system, in the substantia nigra relative to other regions of the brain. Because activated microglia produce increased levels of inflammatory cytokines and chemokines and generate reactive oxygen species that harm DA neurons [35], immune activation in the SNc may influence the onset and progression of the disease, leading to accelerated DA neuron damage and death in PD patients.

Treatment for PD: Current Standard of Care

Presently, there is no cure for PD. The current competition in the global PD therapeutics market is weak because drugs available for treatment provide only symptomatic relief and do not act to reverse disease progression. There is, therefore, an unmet medical need to develop treatments that address the underlying biological causes of the disorder with disease modifying capability therapies to control disease progression.

Early stage PD is typically treated pharmacologically with therapies that replace the dopamine normally secreted by DA neurons in the SNC. Levodopa (L-DOPA), a dopamine precursor that is transformed into dopamine in the brain, is always given with carbidopa, a peripheral dopamine decarboxylase inhibitor that inhibits the metabolism of L-DOPA outside the central nervous system, thereby enhancing its delivery to the brain. Combination carbidopa-levodopa therapies have proven particularly effective at reducing disease symptoms while minimizing side effects of the drugs in the short term; however, these drugs are associated with severe adverse effects with long-term use. Other therapies for early stage PD include dopamine agonists, which mimic the effect of L-DOPA by binding directly to striatal dopamine receptors. Dopamine agonists are often used as first-line therapies, and their early use delays the appearance of motor complications and other dopamine-related symptoms; however, recent reports link them to a variety of behavioral problems [37]. Other adjunctive therapies, such as monoamine oxidase-B inhibitors, which are used to prolong dopamine signaling by blocking dopamine metabolism; catechol O-methyltransferase inhibitors, which work in a similar way; and anticholinergic agents, which have classically been used in younger patients to treat tremor, can provide added relief [38, 39].
Unfortunately, the effectiveness of carbidopa-levodopa-based therapies decreases as the disease progresses, typically within 5 years of treatment initiation [40, 41]. Fluctuations in the response to medication as well as alterations in the production of endogenous l-DOPA result in “off-on” states in which the medication produces alternating phases of good response and no response and/or the development of involuntary movements resulting from dysregulation of dopamine balance. These involuntary movements, dyskinesias, worsen over time, requiring additional therapies to control them, such as amantadine or more aggressive enteral or surgical treatments [39-41]. Deep brain stimulation (DBS) is a relatively new therapy that is increasingly used by physicians. In DBS, electrodes are surgically implanted into one of two specific regions of the basal ganglia, the subthalamic nucleus or the internal globus pallidus [40]. An impulse generator delivers electrical stimuli to the cells and fibers located closest to the implanted electrode, thereby modulating the firing rate and patterns of neurons within the basal ganglia, which in turn influences thalamocortical circuits. DBS is a surgical technique typically used in patients with moderately advanced PD who have disabling off-on fluctuations, dyskinesias, and tremor and who remain responsive to l-DOPA [39, 40]. DBS has been shown to be very effective at reducing the motor symptoms of PD in patients, and numerous clinical trials have demonstrated significant relief [39, 40, 42].

The mechanisms by which DBS relieves PD symptoms remain unclear [40, 43], and the procedure carries risks that concern physicians and patients. Foremost is the potential for infection or intracranial hemorrhage, either of which often require device removal and an extended waiting period before consideration of further implantation surgery. Hardware-related complications, including electrode lead fractures, also occur with high frequency. Finding the optimal DBS stimulation patterns for each patient is also a challenging process of trial and error [43].

A number of other neurological and neuropsychiatric issues can occur with DBS, including cognitive impairment, speech disturbances (particularly with respect to verbal fluency), memory loss, sensory disturbances, and mood disturbances [40, 44, 45]. Although some of these effects may be corrected by adjusting the location of the implant and electrical stimulation, others are permanent or relieved only by cessation of the therapy. Finally, DBS treatment carries significant ongoing expense beyond the initial surgery, owing to the cost of device and battery replacements and ongoing physician visits to monitor stimulation efficacy [43]. In summary, although dopamine-replacement therapies and DBS can provide relief from motor symptoms for patients with PD, they present some important disadvantages, have been received with mixed patient acceptance, and do not treat the underlying causes of the disease.

In addition to the degradation of motor function, PD patients often display a variety of cognitive and psychiatric symptoms, including dementia, hallucinations, anxiety, and depression; disturbances in sleep, bowel or bladder, and sexual functions; and pain [39, 41]. These symptoms significantly diminish patient quality of life [4, 41]. Despite their impact, few clinical trials have directly addressed these issues, and current management of these symptoms in late-stage PD is often poor [39, 40]. Although data from fetal cell transplants suggest that replacing DA neurons likely will not affect these nonmotor symptoms [46], cell replacement may be a clinically competitive option that could lead to significant improvements in the quality of life for patients [47].

Because PD progresses slowly over a period of years to decades, patients often require extensive medical and home care, thereby placing enormous burdens on patients, their families, and society that have been estimated at $25 billion annually in the U.S. alone [48]. Although a variety of therapies treat the motor features of PD, these treatments diminish in efficacy over time. Furthermore, they neither reverse the underlying biological defect nor modify disease progression. Stem cell-based replacement therapies could represent a revolutionary approach that may slow, halt, or reverse many of the motor aspects of PD. In the long term, such an approach might be the best path to a disease-modifying therapy for this devastating neurodegenerative disorder.

**Where Have We Been? History of Cell Transplantation in PD**

The potential of cell-replacement therapies for significant long-term relief of PD symptoms without the need for continued pharmacological or surgical therapy provided the early rationale for conducting transplantation trials using fetal ventral mesencephalic (VM) tissue [49, 50]. The results from these studies will be critical for informing the design of clinical trials to assess the effectiveness of stem cell-based transplantation for PD.

Early open-label trials in Europe and the U.S. showed substantial clinical improvement in some patients receiving fetal cell transplants grafted into the basal ganglia. Studies reported improved motor symptoms [51-55], improved 18F-fluorodopa (18F-DOPA) uptake [53-58] and robust long-term graft survival and reinnervation of the grafted site in these patients [56, 59]. However, two placebo-controlled trials conducted in the U.S., known as the Colorado-Colombia (CC) and Tampa/Mount Sinai/Rush (TMR) trials, showed only modest benefit, if that [60, 61]. Of concern was that a significant proportion of patients appeared to develop graft-induced dyskinesias (GIDs) that persisted even in the absence of levodopa medication [60-62]. These results led to a halt of all cell therapy trials for PD.

Subsequent long-term evaluation of secondary endpoints by PET, 18F-DOPA, and UPDRS scoring, combined with stratification of patients by age and severity, showed a statistically significant benefit of fetal tissue transplantation for certain patient populations. Specifically, younger or less severely affected patients who had been responsive to dopamine-replacement therapy at the time of transplantation showed marked improvement starting 2–4 years after transplantation, in line with reports from the open-label trials [56, 63-66]. Details such as methods for tissue preparation, surgical technique, and immunosuppressive therapy seemed to have particular impact on the success of the intervention, as did the nature of the primary endpoint chosen for use in the study.

In the end, the CC and TMR trials revealed the importance of patient selection, trial design, and rigorous follow-up in clinical trials using cell-replacement therapies. In addition, the clinical endpoints chosen, particularly in the CC trial, were later recognized to be problematic and revealed the importance of defining objective, quantifiable measures as primary endpoints that are assessed some time after surgery when the graft has had a chance to mature and integrate into the host brain.
Furthermore, we now understand the importance of controlling the transplantation procedure itself, including surgical transplantation methods and immunotherapy, to ensure successful outcomes. Finally, studies revealing that patients continued to improve years and even decades after transplantation of fetal VM tissue [63, 67, 68] underscores the importance of including long-term, rigorous follow-up of patients to monitor ongoing changes and improvements in motor symptoms.

To reflect on these findings, the workshop discussed the current efforts to optimize clinical trial design for cell transplantation in PD. A European consortium, TRANSEURO (http://www.transereo.org.uk), will conduct the first fetal cell transplantation study since the CC and TMR trials. The principal objective of TRANSEURO is to develop a safe, long-lasting, and efficacious approach to treating PD patients using fetal cell-based therapeutics that can serve as a template for future clinical trials, including those for other stem cell-based therapies. This clinical trial is being designed using a very tightly controlled approach to minimize procedural variables. It includes specific criteria for selection of the patients (defined age range, stage, and type of PD); tissue preparation (specified number of cells grafted, standardized methods for tissue collection to ensure a high percentage of DA neuroblasts and to limit the number of serotoninergic neurons); and defined methods for tissue placement, graft support, and improved trial design (number of patients, follow-up time, and endpoints). Very careful consideration of the discussions and analysis that have led to this new clinical trial has been reviewed previously [63]. According to TRANSEURO, the primary endpoints for the clinical study are safety and motor effects, but the intent is to evaluate the effects of “tissue preparation and delivery, patient selection and immunosuppressive treatment” and to show that consistency and efficacy of DA cell replacement in PD can be improved by careful attention to those parameters. This study, informed by previous challenges and setbacks, will serve as a valuable resource to inform future stem-cell transplantation studies.

**Challenges and Opportunities Identified in the Workshop**

**Therapeutic Candidate Profile for Stem Cell Therapies**

Stem cell-based replacement therapies could potentially provide lifetime reversal of many of the symptoms of PD. Given the availability of other therapeutic options for PD patients (L-DOPA, enzyme inhibitors, dopamine agonists, DBS) and the risks incurred by surgery, to be clinically competitive, a DA cell therapy should provide long-lasting, major improvement (60–70%) of motor symptoms and suppression of dyskinesias.

Participants in the workshop proposed a therapeutic profile that should be expected for an ideal candidate for cellular therapy (see further detail as described in the Introduction).

Transplanted cells must have the potential to recreate the characteristics of neurons lost to the disease. The principal cell type lost in PD is the A9 DA neuron, found selectively in the SNc. Cell therapy should aim to replace this particular group of DA neurons, supported by in vitro and in vivo data in preclinical animal models. Candidate cells must express the features of authentic nigral A9 DA neurons, such as the right transcriptional and neurophysiological profile (i.e., pacemaker potentials), dopamine production and release in response to physiological stimuli, and significant fiber outgrowth with synapse formation.

Once transplanted into the right anatomical location, DA neurons must survive, reinnervate the striatum, and functionally integrate into the host’s neural circuitry. Consequently, rigorously defining and determining the number of cells required for successful implantation will be essential to achieving lasting survival and integration.

Transplanted neurons must provide measurable, biological outcomes in terms of dopamine synthesis and regulated release on physiological stimuli. The field must place emphasis on the development of potency assays to establish correlations between cell properties in vitro and predictive functional outcomes in vivo. The tools necessary to assess the survival and function of transplanted DA neurons are being developed, and some of these features must be inferred by analyzing the activity of the cells in culture and in large animal models.

Safety issues must be addressed, including tumor formation; GIDs, either through the presence of serotoninergic neurons hyperinnervating the striatum or uneven distribution of transplanted material in the target region; host immunological reactivity to the grafted material; and inappropriate stem cell migration.

Finally, the therapy must result in significant improvement of motor deficits in patients that is robust and sustained over a period of years to decades.

The following sections highlight avenues of current development in stem cell research that were presented and discussed during the workshop and that are directly or indirectly contributing to the development of cells with this therapeutic candidate profile.

**Tools for Modeling PD In Vitro**

The ability to create iPSC cells from human skin biopsies has revolutionized the ability to model numerous neurodegenerative diseases in vitro. Models of Alzheimer’s disease [69, 70], HD [71–74], ALS [75, 76], and autism [77, 78], among others, provide an experimental platform for researchers to investigate disease-specific phenotypes at cellular and molecular levels. This approach could provide invaluable insights for determining the underlying mechanisms of disease and a cell culture system for screening for new therapeutic treatments.

Nonetheless, significant challenges accompany this approach, for example, the ability to overcome clonal variability and minimize the genomic and phenotypic changes that cell lines present over passage and time. One of the proposed solutions for monogenic and genetically defined disorders is to generate isogenic control lines that harbor defined genetic alterations [79] through the use of advanced genome-editing technologies, including zinc-finger nucleases, transcription activator-like effector nucleases, and clustered/regularly interspaced palindromic repeats. Specific sequences can be inserted into the cellular genome to introduce defined mutations (or mutation-corrected sequences) for study [77, 80]. By otherwise preserving all other genetic features of an hiPS cell line, these technologies allow for superior experimental control and can be used to address the challenges associated with clonal variability.

In PD, recent studies using neural cell types derived from human LRRK2-G2019S hiPS cells have revealed increased expression of oxidative stress-response genes and α-synuclein...
protein [32], increased susceptibility to proteosomal [81] and oxidative [24] stress, and key genes and signaling pathways involved in in vitro pathogenesis [82] of the disease. Some of these studies have also shown how isogenic correction of this mutation could reverse several of the identified in vitro phenotypes [81, 82].

A different challenge that the field faced was the need for a repository of well-characterized, publicly available, and diverse hiPS cell lines derived from genetic PD patients. In response, the National Institute of Neurological Disorders and Stroke Parkinson’s Disease iPSC Cell Line Consortium (http://www.pdips.org) initiated the development of such a resource in 2009 [83]. The consortium has already generated iPSC cells from patients with disease-causing mutations for analysis of how cells with different PD-associated genotypes and phenotypes respond to cellular stressors, such as oxidative stress. In addition, although it is unclear whether DA neurons from patients with sporadic PD exhibit the same cellular perturbations observed in genetic forms of the disease, hiPS cell studies can provide an important framework for studying different types of PD. Moreover, hiPS cell models from patients with a diversity of genetic and idiopathic forms will be essential for extracting clinically meaningful information related to disease phenotypes and potential treatments. Promising neuroprotective molecules, for example, could be tested in patient-derived cells to identify a patient’s responsiveness to a given therapy and to understand the mechanisms of disease. In addition, hiPS cell-derived neurons could be used to assess the efficacy of cell-based treatments in vivo and to develop new targets for drug development. Studying these models might lead to new insights into the cellular defects underlying the death of SNc neurons in PD patients. Finally, hiPS cell-based models can be used to optimize neuronal differentiation protocols (e.g., to generate the A9 SNc neurons needed for stem cell transplantation) and to identify conditions that optimize cell survival.

These patient-derived lines can also provide a powerful tool for drug discovery. By grouping the genetic PD iPSC cell lines according to shared cellular phenotypes and the clinical features of the donor patients, this platform could be used for screening of small molecule libraries to identify candidate drugs that modify specific phenotypes, thereby providing a tool to identify patients and at-risk cohorts that may be amenable to specific treatments. Expanding the resource to include data from idiopathic patient hiPS cell lines may provide a means to extrapolate the findings to predict drug responsiveness for different cohorts of this sporadic disorder.

Technologies for Stem Cell Transplantation

Recent advances in stem cell technologies, animal models of PD, and clinical tools will greatly facilitate the goal of stem cell-based therapies for PD. Although workshop participants were optimistic, highlighting a number of key breakthroughs in these areas, they also discussed the ongoing issues that must be addressed to make stem cell-based therapies a viable clinical option.

Stem Cell Source

Because the availability of fetal tissue is restricted, a variety of cell sources suitable for generating mDA neurons has emerged in the past two decades, including in vitro expanded midbrain neural precursors [84–86] and various neural stem cell (NSC) lines [87–89]. However, all of these cell sources and strategies have disadvantages [90]. One is the limited potential of NSC lines to generate authentic mDA neurons. Thus, the group discussed the need for a stem cell source that offers access to the earliest stages of embryonic development, which would allow control of regional specification during cell differentiation.

Human pluripotent stem cells may push the field in a new direction because they provide an alternative source of cells for derivation of DA neurons for therapeutic application and can readily bypass some of the limitations inherent to NSCs [90, 91]. Importantly, translation of any stem cell-based candidate to the clinical setting will require evidence of efficacy, safety, and long term functional efficacy in preclinical models of disease. Presently, both hiPS cell- and hESC-derived sources are being developed as candidates for clinical application.

The history of derivation of mDA neurons provides an object lesson in the challenges inherent in achieving clinical application. Differentiation of this cell type from hESCs was reported nearly a decade ago [22]; however, the field struggled with demonstrating in vivo functional engraftment of these cells. It was not until the development of floor plate-based neuronal differentiation protocols [92–94] that the field made a significant step forward toward the use of these cells for potential clinical cell therapies. Transplantation of these neurons results in robust in vivo survival and therapeutic benefit across rodent and primate PD models, demonstrating both therapeutic efficacy and scalability to large animal models [93].

This differentiation strategy is based on the direct conversion of ESCs to floor plate precursors that, on exposure to Shh and Wnt signaling agonists, are efficiently converted to mDA neurons. Molecular profiling of these cells confirmed a developmental progression of hESCs consistent with the mDA lineage, whereby they correctly coexpressed the transcription factors Foxa2 and Lmx1a at the floor-plate precursor stage and Pitx3 and Nurr1 at later stages of differentiation [93].

This approach has been adopted by other laboratories, which have introduced variations and refinements that have led to some interesting alternatives [92]. Participants felt that work in this area suggests that the floor plate protocol may have translational potential for the development of candidate therapeutic DA cells for transplantation in humans.

Safety

For cell-based therapies to be a viable option for treatment of PD, a number of safety issues must be addressed in preclinical rodent and larger animal models. The major issues appear to be the risk of tumor formation; GIDs, either through the presence of serotonergic neurons hyperinnervating the striatum or uneven distribution of transplanted material in the target region (although it is extremely hard to mimic this problem in the laboratory); host immunological reactivity to the grafted material; and inappropriate stem cell migration. Undifferentiated NSCs have the capacity to undergo extensive migration from the site of transplantation to nontarget sites of the brain through white matter tract. The propensity of stem cells to migrate may result in a theoretical risk that they could cause seizure-like symptoms or other brain dysfunction. The purification (and efficient
differentiation) of cell populations to remove undifferentiated cells, together with methods that yield differentiated precursor cells with high efficiency, will significantly lower the risk for tumor formation and inappropriate migration. Purification to remove serotonergic cells or at least to ensure that their numbers are low relative to midbrain DA neurons, as well as improved surgical methods for distributing cells within the putamen (discussed below), is likely to reduce the incidence of GIDs in patients. Finally, the immune responses to cell transplantation in the brain, particularly the effects of local inflammation on the viability of transplanted cells, are being evaluated [95]; however, it remains unclear how and to what degree the immune system contributes to the long-term viability of grafted material, a question that will be critical to address in the future. That said, it is known that human fetal allografts can survive long term in the adult PD brain in the absence of continuous long-term immunosuppression.

Sorting and Purification
To what degree will cells need to be sorted and purified prior to transplantation? The workshop participants discussed this consideration in a number of contexts. First, pluripotent stem cell-derived populations may pose a risk of tumor formation after transplantation because they can contain undifferentiated or proliferating non-neuronal cells [96, 97]. Furthermore, preclinical evidence suggests that sorted allogeneic cell populations display improved survival and engraftment with reduced incidence of tumor formation [98]. Some procedures are being developed for purifying DA neurons from mixed cultures [98] to remove undifferentiated stem cells and to enrich for cells expressing late differentiation-stage markers, but these differentially purified cell types will need to be systematically tested in vivo. Second, follow-up studies of patients treated with fetal tissue grafts revealed that GIDs could be caused, in part, by the presence of serotonergic cells or at least a high ratio of SER to DA neurons [68, 99, 100]. This suggests that purification to remove this cell type and to further enrich for cell types that produce A9 DA neurons is desirable. Consequently, the effects of sorting and purification on cell transplantation efficacy are an important future area of study.

Scale-Up
A crucial consideration for the clinical application of these cell-based therapies is the scale-up of laboratory protocols to manufacturing processes that are reproducible and predictable and that produce large numbers of cells that are clinically effective, cost effective, and compliant with current good manufacturing practices. Furthermore, the development of strategies for large-scale three-dimensional (3D) manufacturing that more closely mimic the native developmental environment are under way, and advances have been made in the development of small-scale 3D approaches using engineered, chemically defined biomaterials [101, 102]. Importantly, these synthetic environments offer superior control over cell culture conditions while producing desired cell types with significantly improved efficiency, consistency, and reproducibility [102]. It is likely that these bioengineered platforms, together with improvements in small-molecule and other non-integration-based methods for cell differentiation, will lay the foundation for future large-scale cell bioprocessing. This latter step will likely involve partners in industry because most academic laboratories lack the resources for such large-scale manufacturing. Furthermore, an effort should be made to establish collaborations between biology and bioengineering laboratories because it will be necessary to rigorously characterize and test the cells produced using these methods in preclinical models of PD. Nonetheless, the progress initiated and achieved by academic laboratories has been impressive and will be essential to continue this work.

Animal Models to Evaluate Cell Therapy for PD
Preclinical studies in disease models of PD are required to better define the risk-benefit ratio associated with investigational cell therapy products. In addition, use of disease and injury models provides the opportunity for possible identification of activity-risk biomarkers that may be applicable for monitoring in clinical trials [103]. Animal models of PD are good models for motor deficits and include neurotoxic models using compounds (6-OHDA, MPTP, paraquat, or rotenone) that damage the DA system and genetic models that express mutations linked to PD in humans [104]. Neurotoxin-based models produced by 6-OHDA or MPTP administration are the most widely used toxic models, whereas paraquat and rotenone are more recent additions to the stable of toxic agents used to model PD but can be difficult to use. Unilateral injection of 6-OHDA has been shown to cause nigral DA neuron loss, depletion of dopamine, and behavioral deficits that can be quantified easily (e.g., abnormal rotatory behavior in response to amphetamines). Easy behavioral evaluation makes the rodent 6-OHDA lesion the most commonly used animal model. In the 1980s, the 6-OHDA model was used to establish proof-of-principle for human ventral mesencephalic tissue transplantation [105]. However, the 6-OHDA lesion does not recapitulate the clinical features of PD and does not recreate pathologies such as Lewy-like inclusions but is a sensitive model to assay DA nigrostriatal integrity. Furthermore, the comparatively small size of rodent brains makes addressing the issue of scalability challenging in rodents alone. Nonetheless, these model systems are very valuable as a first step toward establishing preclinical proof of concept for cell-replacement therapies.

A second lesion model involves the administration of the neurotoxin MPTP [106], a compound that is selectively taken up by catecholaminergic neurons, including DA neurons, and causes them to die. In primates, MPTP exposure leads to the hallmark behavioral characteristics of PD, including tremors, motor dysfunction, SNC DA neuron damage, and responsiveness of symptoms to L-DOPA treatment [106, 107].

Important early studies by Redmond and colleagues [108, 109] were the first to demonstrate the efficacy of ventral mesencephalic grafts in primate MPTP models of PD. Similar primate models have since been used to show that hESC-derived DA precursors, generated by the floor-plate method, can also efficiently engraft and produce long-lasting benefit [93]. MPTP administration in nonhuman primates is an important model system for validating therapeutic efficacy and scalability of cell-replacement therapies for PD.

Evaluation of the efficacy of a candidate in preclinical studies was identified as a critical issue in the development of cell therapies. The correlation of DA cell loss and striatal innervation with...
Evenly across the striatum, appear to reduce the incidence of GIDs [64, 110]. Improved surgical techniques first pioneered by Francisco described a new surgical tool, known as a radially branched deployment device, that evenly distributes multiple, small cell grafts over a large target region within a single transcortical penetration. There was significant enthusiasm for this tool at the workshop because this surgical approach reduces the likelihood of trauma to other brain regions that can arise with multiple brain penetrations and separate injections. When formulated with materials compatible with functional real-time imaging, such as interventional MRI, radially branched deployment devices may offer an unparalleled ability to monitor the accuracy of targeting during the surgical procedure itself, thereby minimizing the risk of off-target injection and damage to other brain regions [115, 116]. Importantly, by facilitating the even distribution of cell grafts, this delivery platform is likely to reduce the risk of “hot spots” of graft innervation that are thought to influence the development of GIDs. However, the currently available delivery devices used in transplant trials to date are still probably inadequate because the theory of GIDs induced by hot spots comes from a study using a transfrontal delivery approach with needles of tissue. The development of GIDs may have had as much to do with the overall approach as with the device used to deliver the cells.

Research suggests that the extracellular environment critically affects cell survival and differentiation. Dr. David Schaffer from the University of California Berkeley discussed research to develop synthetic bioactive materials that emulate the extrinsic environment. These materials could potentially increase the number and differentiation status of cells generated in vitro and could also be transplanted with cells as a way of affecting their survival and integration into the brain. These extracellular matrix materials have not been tested in animal models yet. This represents another important area in which collaboration between bioengineers and PD researchers may prove valuable.

New Tools to Evaluate Disease Progression and Functional Recovery

Functional neuroimaging techniques such as PET have been important tools for assessing the neuropathology of PD and have helped develop understanding of the mechanisms responsible for the success or failure of grafting human fetal tissue in clinical trials [117]. During the workshop, one of the requirements that emerged for the success of a future cell therapy trial is an optimized functional imaging protocol. Although functional imaging cannot currently be used as a primary endpoint in clinical transplantation trials, if used appropriately, it can provide researchers with an additional valuable in vivo tool alongside clinical observations. Of these neuroimaging methods, radiotracer imaging of the nigrostriatal DA system using 18F-DOPA PET, is among the most accepted methods for monitoring disease progression [118]. A bottleneck in the field is the search for a ligand tagging a specific DA presynaptic terminal location that would allow identification of the survival and growth of the DA-rich graft. To date, 18F-DOPA PET remains the standard for monitoring survival and growth of grafted DA cells. Studies have shown a strong relationship between striatal dopamine deficiency as measured by 18F-DOPA PET and the severity of motor symptoms [117]. However, it is not possible to quantitatively assess DA neuron number using this approach; therefore, the true relationship between tracer uptake and tissue biology remains imperfect [119]. Still, the ability of 18F-DOPA PET to monitor ongoing disease progression that accurately tracks with progression of motor symptoms makes this a usable and reliable biomarker for some aspects of disease progression and monitoring [119], albeit an expensive one.

RECOMMENDATIONS

As described in the Introduction, the workshop identified a series of critical initial steps to facilitate development of a phase I/II clinical trial for stem cell therapy.

Define the Cell Source

Either hiPS cells or hESCs could be used in the first stem cell trial. hESCs provide a more beneficial commercial model because a single hESC line can be banked in large quantities to treat multiple patients. hiPS cells can be autologous or allogeneic. Ideally, pluripotent stem cell banks should be matched to patients to
minimize immune effects. Experiments to evaluate the different cell sources are under way, and several approaches are under investigation. Currently, the effort is focused on prioritizing the different approaches and moving forward into clinical trials with the highest priority.

Choose a Differentiation Protocol That Can Produce Functional Authentic Nigral A9 DA Neurons

It will be critical to select a differentiation protocol that produces the right type of DA neuron, both in vitro and in vivo in animal models. The method of differentiation is currently being optimized in different laboratories. Purification of DA cells from other cells is also necessary to control the ratio of SER to DA neurons in graft preparations and avoid dyskinesias as well as to preclude tumor formation. Animal models should be used to optimize conditions for cell survival, integration, and functional benefits to the animal.

Determine the Minimum Effective Dose and the Maximum Feasible Dose in Large Animal Models

Preclinical experiments in large animal models should be conducted on the selected cell to optimize integration with existing neural circuitry and restoration of function. Although the number of cells required to replace the nigral cell loss is unclear, other cell therapy projects and fetal transplant experiments indicate that it is likely to be around 100,000 DA neurons, assuming they have the same innervation potential as fetal nigral dopamine cells.

Develop Biological Assays That Predict In Vivo Functional Activity and Biological Action

The likelihood of an effective approach for clinical application will increase if cells express the features of authentic nigral A9 DA neurons, such as the right transcriptional and neurophysiologival profile (i.e., pacemaker potentials), dopamine production and release in response to physiological stimuli, and significant fiber outgrowth with synapse formation. Further research is needed to define additional biomarkers and to develop potency assays that provide correlations between cell survival and predictive functional outcome.

Develop a Consistent Transplantation Protocol That Shows Low Risk of Hemorrhage and No Tumor Formation

The first trial should involve bilateral transplantation into the putamen. The physician conducting the transplant would select the optimal method of transplantation, which may include the use of new transplantation devices, but the device for cell delivery is not thought to be a rate-limiting step for the phase I/II trial.

Select Target Patients for the Phase I/II Trial

Given the results from the fetal transplants trials, it seems clear that the target patients should ideally be younger patients who are early in their disease course and responsive to oral dopamine replacement therapies.

Select Outcomes and Follow-up Studies for Phase I/II Trial

Most participants agreed that the patients must be followed for at least 3 years after transplantation. Outcome parameters should include a variety of clinical measures along with MRI and PET.

ACKNOWLEDGMENT

R.C.-A. is currently affiliated with the Foundation for the National Institutes of Health, Bethesda, MD.

AUTHOR CONTRIBUTIONS

R.C.-A.: manuscript writing, final approval of the manuscript; G.P.L., E.G.F., and C.P.: discussion, manuscript editing.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicated no potential conflicts of interest.

REFERENCES

1 Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinson’s disease. Mov Disord 2012;27:597–607.
2 Chaudhuri KR, Odin P, Antonini A et al. Parkinson’s disease: The non-motor issues. Parkinsonism Relat Disord 2011;17:717–723.
3 DeLong MR. The basal ganglia. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science. 4th ed. New York, NY: McGraw Hill, 2000:853–867.
4 Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B et al. Functional organization of the basal ganglia: Therapeutic implications for Parkinson’s disease. Mov Disord 2008;23(suppl 3):S548–S559.
5 Mazzone P, Shabbott B, Cortés JC. Motor control abnormalities in Parkinson’s disease. Cold Spring Harb Perspect Med 2012;2:a009282.
6 Goetz CG, Tilley BC, Shaftman SR et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.
7 Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The unified Parkinson’s disease rating scale (UPDRS): Status and recommendations. Mov Disord 2003;18:738–750.
8 Dryanovski DI, Guzman JN, Xie Z et al. Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J Neurosci 2013;33:10154–10164.
9 Braak H, Del Tredici K, Rüb U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211.
10 Spillantini MG, Schmidt ML, Lee VM et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839–840.
11 Braak H, Del Tredici K, Bratza H et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 2002;249(suppl 3):III/1–III/5.
12 Braak H, Sastre M, Bohl JR et al. Parkinson’s disease: Lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007;113:421–429.
13 Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol 2000;48:485–491.
14 Hardy J, Lewis P, Revesz T et al. The genetics of Parkinson’s syndromes: A critical review. Curr Opin Genet Dev 2009;19:254–265.
15 Polymorphopoulus MH, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 1997;276:2045–2047.
16 Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson’s disease: Progress and therapeutic implications. Mov Disord 2013;28:14–23.
17 Simón-Sánchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic
risk underlying Parkinson’s disease. Nat Genet 2009;41:1308–1312.

18 Do CB, Tung JY, Dorfman E et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s disease. PloS Genet 2011;7:e1002141.

19 Keller MF, Saad M, Bras J et al. Using genome-wide complex trait analysis to quantify ‘missing heritability’ in Parkinson’s disease. Hum Mol Genet 2012;21:4996–5009.

20 Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: Genetics and pathogenesis. Annu Rev Pathol 2011;6:193–222.

21 Sayre LM. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett 1989;48:121–149.

22 Exner N, Lutz AK, Haass E et al. Mitochondrial dysfunction in Parkinson’s disease: Molecular mechanisms and pathophysiological consequences. EMBO J 2012;31:3038–3062.

23 Whitworth AJ, Pallanci U. The PINK1/Parkin pathway: A mitochondrial quality control system? J Bioenerg Biomembr 2009;41:499–503.

24 Cooper O, Seo H, Andrabi S et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med 2012;4:141ra90.

25 Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 2011;70:532–540.

26 de la Fuente-Fernandez R, Schulzer M, Mak E et al. The role of the Lewy body in idiopathic Parkinson disease. Curr Opin Neurol 2012;25:433–447.

27 Okun MS. Deep-brain stimulation for Parkinson’s disease. N Engl J Med 2012;367:1529–1538.

28 Politis M, Wu K, Molloy S et al. Parkinson’s disease symptoms: The patient’s perspective. Mov Disord 2010;25:1646–1651.

29 Krack P, Limousin P, Benabid AL et al. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson’s disease. Lancet 1997;350:1676.

30 Miocinovic S, Somajayula S, Chitnis S et al. History, applications, and mechanisms of deep brain stimulation. JAMA Neurol 2013;70:163–177.

31 Temel Y. Limitic effects of high-frequency stimulation of the subthalamic nucleus. In: Gerl a ld, ed: Vitamins and Hormones. Waltham, MA: Academic Press, 2010:47–63.

32 Parsons TD, Rogers SA, Braaten AJ et al. Cognitive sequelae of subthalamic deep brain stimulation in Parkinson’s disease: A meta-analysis. Lancet Neurol 2006;5:578–588.

33 Politis M, Wu K, Loane C et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated with dopamine grafts. Sci Transl Med 2012;4:128ra41.

34 Lindvall O. Developing dopaminergic cell therapy for Parkinson’s disease—give up or move forward? Mov Disord 2013;28:268–273.

35 Understanding Parkinson’s: Parkinson’s FAQ. Available at http://www.pdf.org/pdf/fs_frequently_asked_questions_10.pdf. Accessed August 12, 2014.

36 Backlund EO, Granberg PO, Hamberger B et al. Transplantation of adrenergic medulla tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985;62:169–173.

37 Lindvall O, Backlund EO, Farde L et al. Transplantation in Parkinson’s disease: Two cases of adrenergic medullary grafts to the putamen. Ann Neurol 1987;22:457–460.

38 Freed CR, Breeze RE. Dopamine cell implantation in Parkinson’s disease: Long-term clinical and (18F)FDOPA PET outcomes. J Nucl Med 2010;51:7–15.

39 Backlund EO, Granberg PO, Hamberger B et al. Transplantation of adrenergic medulla tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985;62:169–173.

40 Backlund EO, Granberg PO, Hamberger B et al. Transplantation of adrenergic medulla tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985;62:169–173.

41 Freed CR, Breeze RE. Parkinson’s disease: The importance of controlled clinical trials. Neurotherapeutics 2011;8:549–561.

42 Wenning GK, Olanow CW, Hoehn and Yahr: The clinical picture. In: Olanow CW, Hallett M, Bhatia KPS, eds: Movement Disorders, 2nd edn. New York: Oxford University Press, 2006:149–159.

43 Widner H et al. Bilateral nigral grafting into the postcomissural putamen in Parkinson’s disease. Ann Neurol 1995;38:379–388.

44 Mak E et al. The role of the Lewy body in idiopathic Parkinson disease. J Neurol 2001;248:422–429.

463 Indoctrination of stem cells for Parkinson’s disease. Nat Med 2007;13:1202–1204.

471 Widner H et al. Bilateral nigral grafting into the postcomissural putamen in Parkinson’s disease. Ann Neurol 1995;38:379–388.

483 Doble KM, Trimm DR, van den Eynde B et al. Dose–response relationship for growth and maturation of midbrain ganglia. Ann Neurol 1994;36:348–355.

493 Collins LM, Toulouse A, Connor TJ et al. Contributions of central and systemic inflammatation to the pathophysiology of Parkinson’s disease. Neuropharmacology 2012;62:2154–2168.

503 Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov Disord 2013;28:715–724.

513 Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson’s disease. Neurol Clin Pract 2012;2:267–274.

523 National Collaborating Centre for Chronic Conditions. Parkinson’s Disease. National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. NICE Clinical Guidelines, No. 35. London, U.K.: Royal College of Physicians, 2006.

533 Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol 2012;25:433–447.

543 Okun MS. Deep-brain stimulation for Parkinson’s disease. N Engl J Med 2012;367:1529–1538.

553 Bradneck W, Boisman D, Tetzlaff J et al. A meta-analysis. Lancet Neurol 2006;5:578–588.

563 Nornes H, Byers B, Cord B et al. LRRK2 mutant iPS- derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011;9:267–280.

573 Dexter DT, Wells FR, Lees AJ et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 1989;52:1830–1836.

583 Sian J, Dexter DT, Lees AJ et al. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348–355.

593 Collins LM, Toulouse A, Connor TJ et al. Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 2012;62:2154–2168.

603 Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov Disord 2013;28:715–724.

613 Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson’s disease. Neurol Clin Pract 2012;2:267–274.

623 National Collaborating Centre for Chronic Conditions. Parkinson’s Disease. National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. NICE Clinical Guidelines, No. 35. London, U.K.: Royal College of Physicians, 2006.
induced pluripotent stem cells. Nature 2012; 482:216–220.
70 Yagi T, Ito D, Okada Y et al. Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet 2011;20: 4530–4539.
71 Cammasio S, Delli Carri A, Lombardo A et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington’s disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012; 46:315–318.
72 Chae JI, Kim DW, Lee N et al. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington’s disease patient. Biochem J 2012;446:359–371.
73 HD IPSC Consortium. Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012;11:264–278.
74 Zhang Z, An MC, Montoro D et al. Characterization of human Huntington’s disease cell model from induced pluripotent stem cells. PLoS Curr 2010;2:RRN1193.
75 Dimos JT, Rodolfa KT, Niakan KK et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218–1221.
76 Egawa N, Kitaoka S et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. 2012;4:145sra104.
77 Marchetto MCN, Carromune C, Acab A et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143: S27–S39.
78 Pasca SP, Portmann T, Voiceaugu I et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011;17:1657–1662.
79 Soldner F, Laganiére J, Cheng AW et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011;146:318–331.
80 Merkle FT, Eggan K. Modeling human disease with pluripotent stem cells: From genome association to function. Cell Stem Cell 2013;12: 656–668.
81 Liu G-H, Qu J, Suzuki K et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012; 491:603–607.
82 Reinhardt P, Schmid B, Burbulla LF et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013;12:354–367.
83 Wray S, Self M, Lewis PA et al. Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS ONE 2012;7:e43099.
84 Parish CL, Castelo-Branco G, Rawal N et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest 2008;118: 149–160.
85 Sánchez-Pernaute R, Studer L, Bankiewicz KS et al. In vitro generation and transplantation of precursor-derived human dopaminergic neurons. J Neurosci Res 2001;65:284–288.
86 Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1998;1:290–295.
87 Andersson ER, Salto C, Villasecusa JC et al. Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. Proc Natl Acad Sci USA 2013;110:E602–E610.
88 Liste I, Garcia-Garcia E, Martinez-Serrano A. The generation of dopaminergic neurons by human neural stem cells is enhanced by Bcl-2. J Neurosci 2004;24: 10786–10795.
89 Wagner J, Akerdal P, Castro DS et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol 1999;17:653–659.
90 Studer L. Derivation of dopaminergic neurons from pluripotent stem cells. Prog Brain Res 2012;200:243–263.
91 Cooper O, Hallett P, Isacson O. Using stem cells and iPS cells to discover new treatments for Parkinson’s disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S14–S53.
92 Kirkeby A, Grealihi S, Wolf DA et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Reports 2012;1:703–714.
93 Krics S, Shim JW, Piao J et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 2011;480:547–551.
94 Fasano CA, Chambers SM, Lee G et al. Efficient derivation of functional floor plate tissue from human embryonic stem cells. Cell Stem Cell 2010;6:336–347.
95 Phillips C, Goud EA, Babu H et al. Natural killer cell-activating receptor NKGD2 mediates innate immune targeting of allogeneic neural progenitor cell grafts. Stem Cells 2013;31:1829–1839.
96 Brederlau A, Correia AS, Anisimov SV et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: Effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006;24:1433–1440.
97 Roy NS, Cleren C, Singh SK et al. Functional engratment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 2006;12:1259–1268.
98 Ganat YM, Calder EL, Kriks S et al. Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engratment. J Clin Invest 2012;122:2928–2939.
99 Carlson T, Carta M, Munoz A et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009;132:319–335.
100 Politis M, Oertel WH, Wu K et al. Graft-induced dyskinesias in Parkinson’s disease: High striatal seroton/n dopaminergic transporter ratio. Mov Disord 2011;26:1997–2003.
101 Ashton RS, Keung AI, Peltier J et al. Progress and prospects for stem cell engineering. Annu Rev Chem Biomol Eng 2011; 2:479–502.
102 Serra M, Brito C, Correia C et al. Process engineering of human pluripotent stem cells for clinical application. Trends Biotechnol 2012;30:350–359.
103 U.S. Food and Drug Administration, Guidance for industry: Preclinical assessment of investigational cellular and gene therapy products; availability. Available at https://www.federalregister.gov/articles/2013/11/25/2013-28173/guidance-for-industry-preclinical-assessment-of-investigational-cellular-and-gene-therapy-products. Published November 25, 2013.
104 Blesaj, Phani S, Jackson-Lewis V et al. Clas sic and new animal models of Parkinson’s disease. J Biomed Biotechnol 2012;2012:845618.
105 Brundin P, Nilsson OG, Stibbe CR et al. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson’s disease. Exp Brain Res 1986;65:235–240.
106 Burns RS, Chiuheh CC, Markey SP et al. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546–4550.
107 Redmond DE Jr., Weiss S, Elsworth JD et al. Cellular repair in the parkinsonian nonhuman primate brain. Rejuvenation Res 2010;13: 188–194.
108 Redmond DE Jr., Naftolin F, Collier TJ et al. Cryopreservation, culture, and transplantation of human fetal mesencephalic tissue into monkeys. Science 1988;242:768–771.
109 Redmond DE, Sladek JR Jr., Roth RH et al. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1986; 1:1125–1127.
110 Mariés E, Kordower JH, Chu Y et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis 2006;21:165–180.
111 Mendez I, Hong M, Smith S et al. Neural transplantation cannula and microinjector system: Experimental and clinical experience. Technical note. J Neurosurg 2000;92:493–499.
112 Mendez I, Sadi D, Hong M. Reconstruction of the nigrostriatal pathway by simultaneous intrastratal and intranigral dopaminergic transplants. J Neurosci 1996;16: 7216–7227.
113 Mendez I, Sanchez-Pernaute R, Cooper O et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the streptozotocin and substantia nigra of patients with Parkinson’s disease. Brain 2005;128:1498–1510.
114 Mendez I, Vihuela A, Astradsson A et al. Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat Med 2008;14:507–509.

©AlphaMed Press 2014
Potts MB, Silvestrini MT, Lim DA. Devices for cell transplantation into the central nervous system: Design considerations and emerging technologies. Surg Neurol Int 2013;4(suppl 1):S22–S30.

Roskom J, Swistowski A, Zeng X et al. Future directions: Use of interventional MRI for cell-based therapy of Parkinson disease. Neurosurg Clin N Am 2009;20:211–218.

Politis M, Piccini P. In vivo imaging of the integration and function of nigral grafts in clinical trials. Prog Brain Res 2012;200:199–220.

Politis M. Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson’s disease. BMC Med 2011;9:50.

Ravina B, Eidelberg D, Ahlskog JE et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208–215.

See www.StemCellsTM.com for supporting information available online.

To join the conversation, please visit the Stem Cells Portal at http://StemCellsPortal.com/content/2014-0146